Evidence map›Paper›PMID 41711915›Full record

SynthesisDermatologie (Heidelberg, Germany)2026

[Pruritus-strong predictor of treatment response in lichen planus pigmentosus inversus].

Thilo Gambichler, Ocko Kautz, Stefanie Boms, Laura Susok

Abstract readEnglish AbstractSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thilo GambichlerKlinik für Dermatologie, Klinikum Dortmund gGmbH, Universität Witten/Herdecke, Dortmund, Deutschland. t.gambichler@hospitalverbund.de.
Ocko KautzMVZ Dermatologie & Histologie Westerstede, 26655, Westerstede, Deutschland.
Stefanie BomsKlinik für Dermatologie, Christliches Klinikum Unna, Obere Husemannstr. 2, 59423, Unna, Deutschland.
Laura SusokKlinik für Dermatologie, Klinikum Dortmund gGmbH, Universität Witten/Herdecke, Dortmund, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lichen planus pigmentosus inversus (LIPPI) is a rare variant of lichen planus, predominantly affecting intertriginous skin areas. Existing knowledge is mostly based on case reports, with few systematic reviews available. A systematic literature search identified 105 cases from case reports and series. Extracted data included demographics, clinical features, comorbidities, treatments, and outcomes. Statistical analysis included descriptive methods and uni-/multivariate logistic regression. The cohort was 64.8% female, with a median age of 58 years. Most lesions affected multiple inverse areas (55.2%). Pruritus was reported only in 44.8% of patients. Median time to diagnosis was 6 months. Treatment response was observed in 47.6% of cases, mostly with topical corticosteroids or calcineurin inhibitors. Pruritus proved to be a strong predictor of treatment response (odds ratio [OR] 4.17), as did, to a lesser extent, shorter disease duration until diagnosis (OR 0.93 per month). Ethnicity and comorbidities had no significant effect in multivariate analysis. LIPPI presents with considerable clinical and demographic variability. Pruritus and early diagnosis may be associated with better treatment outcomes and could serve as relevant prognostic indicators.

Indexed as

Lichen PlanusPruritusAdrenal Cortex HormonesCalcineurin InhibitorsHumansPrognosisTreatment OutcomeAdrenal Cortex HormonesCalcineurin InhibitorsDisease managementInterface dermatitisIntertrigoMelanophagesPigment incontinence

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.